Information Provided By:
Fly News Breaks for February 26, 2020
BTAI
Feb 26, 2020 | 07:38 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BioXcel Therapeutics to $95 from $30 and reiterates a Buy rating on the shares. Following an assessment of the five indications in which BXCL501 could potentially be deployed, schizophrenia, bipolar disorder, Alzheimer's disease, opioid use disorder and acute delirium , the analyst instituted an updated valuation assessment. His assessment yields a total value of $2B for BXCL501 across the aforementioned indications.
News For BTAI From the Last 2 Days
There are no results for your query BTAI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.